PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33450317-6 2021 To overcome therapeutic efficiency limitations against TRAIL-resistant tumors, we exploited the characteristic of a naturally derived nanocage that not only delivers TRAIL in its native-like trimeric structure, but also delivers a drug (doxorubicin [DOX]) that re-sensitizes TRAIL-resistant tumor cells. Doxorubicin 237-248 TNF superfamily member 10 Homo sapiens 55-60 33450317-7 2021 These TRAIL-presenting nanocages (TTPNs) showed high loading efficiency, pH-dependent release profiles, and effective intracellular delivery of the re-sensitizing agent DOX. Doxorubicin 169-172 TNF superfamily member 10 Homo sapiens 6-11 33450317-8 2021 As a result, DOX-TTPNs efficiently re-sensitized TRAIL-resistant tumor cells to TRAIL-mediated apoptosis in vitro by regulating levels of the TRAIL receptor, DR5, and anti- and pro-apoptotic proteins involved in extrinsic and intrinsic apoptosis pathways. Doxorubicin 13-16 TNF superfamily member 10 Homo sapiens 49-54 33450317-8 2021 As a result, DOX-TTPNs efficiently re-sensitized TRAIL-resistant tumor cells to TRAIL-mediated apoptosis in vitro by regulating levels of the TRAIL receptor, DR5, and anti- and pro-apoptotic proteins involved in extrinsic and intrinsic apoptosis pathways. Doxorubicin 13-16 TNF superfamily member 10 Homo sapiens 80-85 33450317-9 2021 We further demonstrated the antitumor efficacy of DOX-TTPNs in vivo, showing that even at a very low dose, the incorporated DOX successfully re-sensitized tumors to the apoptotic effects of TRAIL, underscoring the potential of this platform as an antitumor agent. Doxorubicin 50-53 TNF superfamily member 10 Homo sapiens 190-195 33450317-9 2021 We further demonstrated the antitumor efficacy of DOX-TTPNs in vivo, showing that even at a very low dose, the incorporated DOX successfully re-sensitized tumors to the apoptotic effects of TRAIL, underscoring the potential of this platform as an antitumor agent. Doxorubicin 124-127 TNF superfamily member 10 Homo sapiens 190-195 32365976-3 2020 We have demonstrated that the combination of TRAIL with doxorubicin, bortezomib, and panobinostat dramatically reduced the viability of TRAIL-resistant A549 and HT-29 cells. Doxorubicin 56-67 TNF superfamily member 10 Homo sapiens 136-141 33321722-6 2020 In comparison to free drug, we observed that Tf-bound DOX induced apoptosis in a TRAIL-dependent manner and caused DNA damage typical of programmed cell death. Doxorubicin 54-57 TNF superfamily member 10 Homo sapiens 81-86 31817469-4 2019 In this study, we have improved LUV-TRAIL by loading doxorubicin (DOX) in its liposomal lumen (LUVDOX-TRAIL) in order to improve their cytotoxic potential. Doxorubicin 53-64 TNF superfamily member 10 Homo sapiens 36-41 31817469-4 2019 In this study, we have improved LUV-TRAIL by loading doxorubicin (DOX) in its liposomal lumen (LUVDOX-TRAIL) in order to improve their cytotoxic potential. Doxorubicin 53-64 TNF superfamily member 10 Homo sapiens 102-107 31817469-4 2019 In this study, we have improved LUV-TRAIL by loading doxorubicin (DOX) in its liposomal lumen (LUVDOX-TRAIL) in order to improve their cytotoxic potential. Doxorubicin 66-69 TNF superfamily member 10 Homo sapiens 36-41 31817469-4 2019 In this study, we have improved LUV-TRAIL by loading doxorubicin (DOX) in its liposomal lumen (LUVDOX-TRAIL) in order to improve their cytotoxic potential. Doxorubicin 66-69 TNF superfamily member 10 Homo sapiens 102-107 31817469-6 2019 In addition, the concerted action of the liposomal DOX and TRAIL was specific of the liposomal DOX and was not observed when with soluble DOX. Doxorubicin 95-98 TNF superfamily member 10 Homo sapiens 59-64 31817469-6 2019 In addition, the concerted action of the liposomal DOX and TRAIL was specific of the liposomal DOX and was not observed when with soluble DOX. Doxorubicin 95-98 TNF superfamily member 10 Homo sapiens 59-64 31817469-7 2019 The cytotoxicity induced by LUVDOX-TRAIL was proven to rely on two processes due to different molecular mechanisms: a dynamin-mediated internalization of the doxorubicin-loaded particle, and the strong activation of caspase-8 exerted by the liposomal TRAIL. Doxorubicin 158-169 TNF superfamily member 10 Homo sapiens 35-40 29521001-2 2018 We compare customized microbubbles of different polymeric shell compositions, and investigate the effect of both shell composition and incorporation of doxorubicin on action against TRAIL-sensitive MDA-MB-231 and TRAIL-resistant MCF7 human breast adenocarcinoma cells. Doxorubicin 152-163 TNF superfamily member 10 Homo sapiens 182-187 29521001-6 2018 Co-encapsulation of doxorubicin within the contrast agent shell increased MDA-MB-231 cell death to approximately 40-80%, representing a marked increase over TRAIL alone, reflecting the dramatic effect of shell composition. Doxorubicin 20-31 TNF superfamily member 10 Homo sapiens 157-162 29521001-7 2018 Additionally, shells that co-encapsulated TRAIL and doxorubicin resulted in approximately 30-60% death in TRAIL-resistant MCF7 human breast adenocarcinoma cells, compared with little apoptotic response in these cells from shells encapsulating TRAIL alone, demonstrating the sensitization effect of the drug. Doxorubicin 52-63 TNF superfamily member 10 Homo sapiens 106-111 29521001-7 2018 Additionally, shells that co-encapsulated TRAIL and doxorubicin resulted in approximately 30-60% death in TRAIL-resistant MCF7 human breast adenocarcinoma cells, compared with little apoptotic response in these cells from shells encapsulating TRAIL alone, demonstrating the sensitization effect of the drug. Doxorubicin 52-63 TNF superfamily member 10 Homo sapiens 106-111 29263663-2 2017 In this project, the human tumor necrosis factor-related apoptosis-inducing ligand-encoding plasmid gene (TRAIL) and doxorubicin (Dox)-coloaded multi-functional nanocarrier was constructed based on the theory of circulation, accumulation, internalization, and release. Doxorubicin 130-133 TNF superfamily member 10 Homo sapiens 27-104 29268009-1 2018 Two novel alpha-tocopheryl-lipoic acid conjugates (TL1 and TL2) were synthesized for the anticancer drug, doxorubicin (DOX), delivery. Doxorubicin 106-117 TNF superfamily member 10 Homo sapiens 59-62 29268009-1 2018 Two novel alpha-tocopheryl-lipoic acid conjugates (TL1 and TL2) were synthesized for the anticancer drug, doxorubicin (DOX), delivery. Doxorubicin 119-122 TNF superfamily member 10 Homo sapiens 59-62 29268009-7 2018 The encapsulation efficiency of a commonly used anticancer drug, doxorubicin (DOX), in nanovesicles was found to be ~60% and ~55% for TL1 and TL2, respectively (TL1-DOX and TL2-DOX). Doxorubicin 65-76 TNF superfamily member 10 Homo sapiens 142-145 29268009-7 2018 The encapsulation efficiency of a commonly used anticancer drug, doxorubicin (DOX), in nanovesicles was found to be ~60% and ~55% for TL1 and TL2, respectively (TL1-DOX and TL2-DOX). Doxorubicin 65-76 TNF superfamily member 10 Homo sapiens 173-176 29268009-7 2018 The encapsulation efficiency of a commonly used anticancer drug, doxorubicin (DOX), in nanovesicles was found to be ~60% and ~55% for TL1 and TL2, respectively (TL1-DOX and TL2-DOX). Doxorubicin 78-81 TNF superfamily member 10 Homo sapiens 142-145 29268009-7 2018 The encapsulation efficiency of a commonly used anticancer drug, doxorubicin (DOX), in nanovesicles was found to be ~60% and ~55% for TL1 and TL2, respectively (TL1-DOX and TL2-DOX). Doxorubicin 78-81 TNF superfamily member 10 Homo sapiens 173-176 28300219-6 2017 Furthermore, TRAIL potentiated doxorubicin-induced decrease in beating rate and amplitude of iPS-derived cardiomyocytes. Doxorubicin 31-42 TNF superfamily member 10 Homo sapiens 13-18 28771937-6 2017 Additionally, the MBs were designed to co-encapsulate the chemotherapeutic doxorubicin (Dox) within the shell that works with TRAIL to sensitize resistant cells. Doxorubicin 75-86 TNF superfamily member 10 Homo sapiens 126-131 28771937-6 2017 Additionally, the MBs were designed to co-encapsulate the chemotherapeutic doxorubicin (Dox) within the shell that works with TRAIL to sensitize resistant cells. Doxorubicin 88-91 TNF superfamily member 10 Homo sapiens 126-131 28702823-5 2017 In the TRAIL pre-treated cells, ET and DOX induced higher apoptosis, indicating their synergistic effect with TRAIL. Doxorubicin 39-42 TNF superfamily member 10 Homo sapiens 7-12 28702823-5 2017 In the TRAIL pre-treated cells, ET and DOX induced higher apoptosis, indicating their synergistic effect with TRAIL. Doxorubicin 39-42 TNF superfamily member 10 Homo sapiens 110-115 28702823-7 2017 The binding energy for TRAIL-DR5 complexation in the ternary complexes containing ET (-111.08 kcal/mol) and DOX (-76.35 kcal/mol) were higher than reported binding energy of binary complex (-53.70 kcal/mol). Doxorubicin 108-111 TNF superfamily member 10 Homo sapiens 23-28 28814080-7 2017 Ligation of TRAIL reduced the encapsulation efficiency for Dox compared to those of their non-ligated counterparts (p < 0.0001) by approximately 34% for 100% PLA, 23% for 5 wt % PEG-PLA, and 30% for the 1 wt % LipidPEG platform. Doxorubicin 59-62 TNF superfamily member 10 Homo sapiens 12-17 28702823-0 2017 Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Doxorubicin 14-25 TNF superfamily member 10 Homo sapiens 106-111 27557520-3 2016 The LHRss/DOX/TRAIL construct has reduction-sensitive behavior and an enhanced endosomal escape ability to increase the cytotoxicity of DOX and the transfection efficiency. Doxorubicin 10-13 TNF superfamily member 10 Homo sapiens 14-19 27557520-3 2016 The LHRss/DOX/TRAIL construct has reduction-sensitive behavior and an enhanced endosomal escape ability to increase the cytotoxicity of DOX and the transfection efficiency. Doxorubicin 136-139 TNF superfamily member 10 Homo sapiens 14-19 27557520-4 2016 Further, the LHRss/DOX/TRAIL construct increased the accumulation of DOX and promoted the expression of pTRAIL, thus increasing cellular apoptosis by 83.7% in MCF-7/ADR cells. Doxorubicin 19-22 TNF superfamily member 10 Homo sapiens 23-28 27557520-4 2016 Further, the LHRss/DOX/TRAIL construct increased the accumulation of DOX and promoted the expression of pTRAIL, thus increasing cellular apoptosis by 83.7% in MCF-7/ADR cells. Doxorubicin 69-72 TNF superfamily member 10 Homo sapiens 23-28 27557520-5 2016 In addition, the in vivo biodistribution results showed that the LHRss/DOX/TRAIL construct could target tumors well. Doxorubicin 71-74 TNF superfamily member 10 Homo sapiens 75-80 27557520-6 2016 The in vivo anti-tumor effect study demonstrated that the LHRss/DOX/TRAIL construct inhibited tumor growth markedly, with a tumor inhibitory rate of 94.0%. Doxorubicin 64-67 TNF superfamily member 10 Homo sapiens 68-73 26641559-1 2016 Crosslinked albumin nanoparticles which loaded with doxorubicin (DOX) were fabricated with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and biocompatible polysaccharide, alginate (ALG), using layer-by-layer technique. Doxorubicin 52-63 TNF superfamily member 10 Homo sapiens 148-153 26641559-1 2016 Crosslinked albumin nanoparticles which loaded with doxorubicin (DOX) were fabricated with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and biocompatible polysaccharide, alginate (ALG), using layer-by-layer technique. Doxorubicin 65-68 TNF superfamily member 10 Homo sapiens 91-146 26641559-1 2016 Crosslinked albumin nanoparticles which loaded with doxorubicin (DOX) were fabricated with tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and biocompatible polysaccharide, alginate (ALG), using layer-by-layer technique. Doxorubicin 65-68 TNF superfamily member 10 Homo sapiens 148-153 26641559-5 2016 In addition, after loaded into the albumin core nanoparticles, DOX (as the chemotherapeutics) display a synergistic cytotoxic effect on cytotoxicity in combination with TRAIL in vitro. Doxorubicin 63-66 TNF superfamily member 10 Homo sapiens 169-174 26526555-0 2016 Doxorubicin-Bound Albumin Nanoparticles Containing a TRAIL Protein for Targeted Treatment of Colon Cancer. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 53-58 26526555-2 2016 METHODS: TRAIL (0.2, 0.4, 1.0%)- and Dox-loaded HSA nanoparticles (TRAIL/Dox HSA NPs) were prepared by using the nab(TM) technology. Doxorubicin 37-40 TNF superfamily member 10 Homo sapiens 67-72 26526555-8 2016 TRAIL 1.0%/Dox HSA NPs displayed the best inhibition of HCT116 colon cancer cells; inhibition was 6 times higher than achieved with Dox HSA NPs. Doxorubicin 132-135 TNF superfamily member 10 Homo sapiens 0-5 26526555-10 2016 Flow cytometry analysis and TUNEL assay revealed that TRAIL 1.0%/Dox HSA NPs had markedly greater apoptotic activity than Dox HSA NPs. Doxorubicin 65-68 TNF superfamily member 10 Homo sapiens 54-59 26526555-11 2016 In HCT116 tumor-bearing BALB/c nu/nu mice, TRAIL 1.0%/Dox HSA NPs had significantly higher antitumor efficacy than Dox HSA NPs (tumor volume; 933.4 mm(3) vs. 3183.7 mm(3), respectively). Doxorubicin 54-57 TNF superfamily member 10 Homo sapiens 43-48 26526555-13 2016 CONCLUSIONS: Data indicate that TRAIL 1.0%/Dox HSA NPs offer advantages of co-delivery of Dox and TRAIL in tumors, with potential synergistic apoptosis-based anticancer therapy. Doxorubicin 43-46 TNF superfamily member 10 Homo sapiens 98-103 26526555-13 2016 CONCLUSIONS: Data indicate that TRAIL 1.0%/Dox HSA NPs offer advantages of co-delivery of Dox and TRAIL in tumors, with potential synergistic apoptosis-based anticancer therapy. Doxorubicin 90-93 TNF superfamily member 10 Homo sapiens 32-37 26794656-8 2016 Finally, both myricetin and spinacine sensitized HPV(+) cervical and oral cancer cells, but not HPV(-) cervical and oral cancer cells, to apoptosis induced by the cancer-specific ligand TRAIL, as well as the chemotherapeutic agents doxorubicin and cisplatin. Doxorubicin 232-243 TNF superfamily member 10 Homo sapiens 186-191 26547077-7 2015 Chemotherapeutic drugs such as doxorubicin, paclitaxel, and bortezomib augmented the effect of both TRAIL variants, and the enhancing effect was more pronounced for DR5-B. Doxorubicin 31-42 TNF superfamily member 10 Homo sapiens 100-105 26227206-3 2015 Here, we tested whether TRAIL-expressing hMSCs, in combination with a sub-toxic-dose of a chemotherapy drug doxorubicin, would overcome TRAIL resistance and create synergistic effects on targeting metastatic TNBC. Doxorubicin 108-119 TNF superfamily member 10 Homo sapiens 136-141 26227206-6 2015 Furthermore, activated hMSCs increased apoptosis in MDA cells when combined with a sub-toxic dose of doxorubicin, which was mediated by up-regulating TRAIL and Fas-related pathways. Doxorubicin 101-112 TNF superfamily member 10 Homo sapiens 150-155 26227206-8 2015 CONCLUSIONS: These results suggest that the treatment of hMSCs with a sub-toxic dose of doxorubicin can overcome TRAIL resistance and be a potential novel therapy for TNBC metastasis treatment. Doxorubicin 88-99 TNF superfamily member 10 Homo sapiens 113-118 22133146-5 2012 Comparative proteomic analysis between whole cell lysates of Dox-TRAIL and control samples revealed 56 differentially expressed spots (>=2-fold change and p < 0.05) common to at least two cell lines. Doxorubicin 61-64 TNF superfamily member 10 Homo sapiens 65-70 25445703-5 2015 TRAIL/Dox HSA-NP displayed synergistic cytotoxicity and apoptotic activity in H226 lung cancer cells vs. HSA-NP containing TRAIL or Dox alone. Doxorubicin 132-135 TNF superfamily member 10 Homo sapiens 0-5 24013224-0 2014 Inhibition of the mitochondrial pyrimidine biosynthesis enzyme dihydroorotate dehydrogenase by doxorubicin and brequinar sensitizes cancer cells to TRAIL-induced apoptosis. Doxorubicin 95-106 TNF superfamily member 10 Homo sapiens 148-153 24013224-3 2014 Chemotherapeutic agents, such as doxorubicin have been shown to act synergistically with TRAIL, but the exact mechanisms of actions are poorly understood. Doxorubicin 33-44 TNF superfamily member 10 Homo sapiens 89-94 24013224-4 2014 In this study, we performed high-throughput small interfering RNA screening and genome-wide gene expression profiling on doxorubicin-treated U1690 cells to explore novel mechanisms underlying doxorubicin-TRAIL synergy. Doxorubicin 121-132 TNF superfamily member 10 Homo sapiens 204-209 24013224-4 2014 In this study, we performed high-throughput small interfering RNA screening and genome-wide gene expression profiling on doxorubicin-treated U1690 cells to explore novel mechanisms underlying doxorubicin-TRAIL synergy. Doxorubicin 192-203 TNF superfamily member 10 Homo sapiens 204-209 32260806-1 2013 Layer-by-layer assembled TRAIL/ALG shells have been successfully coated on the surface of highly loaded doxorubicin (DOX) calcium carbonate (CaCO3) nanoparticles as drug carriers. Doxorubicin 104-115 TNF superfamily member 10 Homo sapiens 25-30 32260806-1 2013 Layer-by-layer assembled TRAIL/ALG shells have been successfully coated on the surface of highly loaded doxorubicin (DOX) calcium carbonate (CaCO3) nanoparticles as drug carriers. Doxorubicin 117-120 TNF superfamily member 10 Homo sapiens 25-30 32260806-3 2013 They show that the assembled TRAIL/ALG coated DOX@CaCO3 nanocomposites can be internalized by cancer cells. Doxorubicin 46-49 TNF superfamily member 10 Homo sapiens 29-34 32260806-6 2013 This demonstrates that the core/shell nanocomposites of TRAIL/ALG-CaCO3 loaded with DOX have good potential applications in the treatment of cancer. Doxorubicin 84-87 TNF superfamily member 10 Homo sapiens 56-61 23993342-3 2013 Firstly, DOX was intercalated into Trail to form a stable complex. Doxorubicin 9-12 TNF superfamily member 10 Homo sapiens 35-40 23993342-4 2013 Secondly, DOX-Trail complex was condensed by Dendrigraft poly-L-lysine (DGL) to form a nanoscaled co-delivery system. Doxorubicin 10-13 TNF superfamily member 10 Homo sapiens 14-19 23504627-0 2013 Doxorubicin sensitizes human tumor cells to NK cell- and T-cell-mediated killing by augmented TRAIL receptor signaling. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 94-99 23504627-5 2013 The central role of the TRAIL signaling pathway was further supported by an increased expression of TRAIL-R2 on DOX-treated tumor cells and by downregulation of cellular FLICE inhibitory protein, the inhibitors of death receptor-mediated apoptosis. Doxorubicin 112-115 TNF superfamily member 10 Homo sapiens 24-29 24332050-0 2013 [Effect of doxorubicin on TRAIL resistance and TRAIL receptor expression in lymphoma cell line SNK-6 cells]. Doxorubicin 11-22 TNF superfamily member 10 Homo sapiens 26-31 24332050-1 2013 OBJECTIVE: To investigate the effect of doxorubicin on TRAIL resistance and TRAIL receptor expression in lymphoma cell line SNK-6 cells. Doxorubicin 40-51 TNF superfamily member 10 Homo sapiens 55-60 24332050-2 2013 METHODS: SNK-6 cells treated with doxorubicin at different concentrations alone or in combination with tumor necrosis factor related apoptosis inducing ligand (TRAIL). Doxorubicin 34-45 TNF superfamily member 10 Homo sapiens 103-158 24332050-5 2013 RESULTS: MTT assay showed that treatment with 100 and 1000 ng/ml doxorubicin for 24 h, the survival rates of SNK-6 cells were (80.9 +- 7.2)% and (53.7 +- 2.8)%, significantly higher than that by treatment combined with 500 ng/ml TRAIL (64.9 +- 1.1)% and (34.0 +- 3.9)%, respectively (P < 0.05). Doxorubicin 65-76 TNF superfamily member 10 Homo sapiens 229-234 24332050-6 2013 Flow cytometry showed that after treatment with 100 and 1000 ng/ml doxorubicin for 48 h, the survival rates of SNK-6 cells were (69.9 +- 6.1)% and (31.1 +- 1.9)%, while treated in combination with 500 ng/ml TRAIL, the cell survival rates were (37.5 +- 6.4)% and (15.0 +- 1.8)%, respectively. Doxorubicin 67-78 TNF superfamily member 10 Homo sapiens 207-212 24332050-8 2013 The expressions of TRAIL receptors and decoy receptors were increased when SNK-6 cells were treated with 100 ng/ml doxorubicin for 24 hours. Doxorubicin 115-126 TNF superfamily member 10 Homo sapiens 19-24 24332050-9 2013 CONCLUSIONS: Doxorubicin can overcome to a certain extent the TRAIL resistance of SNK-6 cells and induce upregulation of TRAIL death receptors and decoy receptors on the surface of SNK-6 cells. Doxorubicin 13-24 TNF superfamily member 10 Homo sapiens 62-67 24332050-9 2013 CONCLUSIONS: Doxorubicin can overcome to a certain extent the TRAIL resistance of SNK-6 cells and induce upregulation of TRAIL death receptors and decoy receptors on the surface of SNK-6 cells. Doxorubicin 13-24 TNF superfamily member 10 Homo sapiens 121-126 23142520-5 2012 TRAIL was further upregulated by apoptotic MDA cells in a TLR3-dependent manner; this feedforward cycle increased MDA cell apoptosis, and the chemotherapeutic drug doxorubicin had a synergistic effect. Doxorubicin 164-175 TNF superfamily member 10 Homo sapiens 0-5 22753761-0 2012 TRAIL and taurolidine enhance the anticancer activity of doxorubicin, trabectedin and mafosfamide in HT1080 human fibrosarcoma cells. Doxorubicin 57-68 TNF superfamily member 10 Homo sapiens 0-5 22753761-9 2012 CONCLUSION: When combined with TRAIL and taurolidine, treatment with doxorubicin and trabectedin demonstrated stronger apoptosis-inducing and antiproliferative effects. Doxorubicin 69-80 TNF superfamily member 10 Homo sapiens 31-36 22484049-2 2012 In this paper, we designed a co-delivery system (DGDPT/pORF-hTRAIL) loading chemotherapeutic drug doxorubicin and gene agent pORF-hTRAIL, and with functions of pH-trigger and cancer targeting. Doxorubicin 98-109 TNF superfamily member 10 Homo sapiens 60-66 21855130-6 2011 DOX and PEG-TRAIL release from dual agent microspheres were biologically active and significantly inhibited the TRAIL-sensitive HCT116 and resistant PC-3 cells in vitro. Doxorubicin 0-3 TNF superfamily member 10 Homo sapiens 112-117 22118776-6 2012 Results showed that the TRAIL/transferrin/doxorubicin HSA-NPs had remarkable cytotoxic and apoptotic activities in all cancer cells examined with a general or a drug-resistant character, and that these NPs had obvious synergistic cytotoxic effects particularly on CAPAN-1 cells. Doxorubicin 42-53 TNF superfamily member 10 Homo sapiens 24-29 22077238-6 2012 In contrast, another anthracycline, doxorubicin (DOX), only slightly sensitized Jurkat cells and A549 cells to TRAIL-induced apoptosis, with weaker enhancement of death receptor 5 (DR5) expression than ACR. Doxorubicin 36-47 TNF superfamily member 10 Homo sapiens 111-116 22077238-6 2012 In contrast, another anthracycline, doxorubicin (DOX), only slightly sensitized Jurkat cells and A549 cells to TRAIL-induced apoptosis, with weaker enhancement of death receptor 5 (DR5) expression than ACR. Doxorubicin 49-52 TNF superfamily member 10 Homo sapiens 111-116 21609741-3 2011 Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 45-50 21609741-3 2011 Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 113-118 21609741-3 2011 Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 113-118 21609741-3 2011 Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. Doxorubicin 13-16 TNF superfamily member 10 Homo sapiens 45-50 21609741-3 2011 Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. Doxorubicin 13-16 TNF superfamily member 10 Homo sapiens 113-118 21609741-3 2011 Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. Doxorubicin 13-16 TNF superfamily member 10 Homo sapiens 113-118 21609741-3 2011 Doxorubicin (DOX) can sensitize GBM cells to TRAIL-induced apoptosis, indicating that the combination of DOX and TRAIL may be an effective strategy to kill TRAIL-resistant GBM cells. Doxorubicin 105-108 TNF superfamily member 10 Homo sapiens 45-50 21586819-3 2011 Doxorubicin (DOX) can sensitize NSCLC cells to TRAIL-induced apoptosis, indicating the possibility of combination therapy. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 47-52 21514380-6 2011 Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype. Doxorubicin 91-102 TNF superfamily member 10 Homo sapiens 13-18 21514380-6 2011 Furthermore, TRAIL significantly potentiated the cytotoxicity of vinblastine, vincristine, doxorubicin and VP-16 that are P-gp substrate anticancer drugs in both MDR cells, which resulted in the reversal effect of TRAIL on the MDR phenotype. Doxorubicin 91-102 TNF superfamily member 10 Homo sapiens 214-219 21586819-3 2011 Doxorubicin (DOX) can sensitize NSCLC cells to TRAIL-induced apoptosis, indicating the possibility of combination therapy. Doxorubicin 13-16 TNF superfamily member 10 Homo sapiens 47-52 21586819-4 2011 Unfortunately, the therapeutic effect of a DOX and TRAIL combination is limited by multiple factors including the short serum half-life of TRAIL, poor compliance and application difficulty in the clinic, chronic DOX-induced cardiac toxicity, and the multidrug resistance (MDR) property of NSCLC cells. Doxorubicin 43-46 TNF superfamily member 10 Homo sapiens 139-144 21586819-4 2011 Unfortunately, the therapeutic effect of a DOX and TRAIL combination is limited by multiple factors including the short serum half-life of TRAIL, poor compliance and application difficulty in the clinic, chronic DOX-induced cardiac toxicity, and the multidrug resistance (MDR) property of NSCLC cells. Doxorubicin 212-215 TNF superfamily member 10 Homo sapiens 51-56 20482316-0 2010 Cathepsin E enhances anticancer activity of doxorubicin on human prostate cancer cells showing resistance to TRAIL-mediated apoptosis. Doxorubicin 44-55 TNF superfamily member 10 Homo sapiens 109-114 20971503-3 2011 The result of fluorescence scanning showed that about 375 DOX molecules were bound to one pORF-hTRAIL molecule. Doxorubicin 58-61 TNF superfamily member 10 Homo sapiens 95-101 20971503-4 2011 The co-delivery system was constructed based on the electrostatic interactions between pORF-hTRAIL-DOX complex and cationic PAMAM-PEG-T7. Doxorubicin 99-102 TNF superfamily member 10 Homo sapiens 92-98 20659427-8 2010 And also, HIF-1alpha inactivating reagents including DOX increased the sensitivity to TRAIL protein in tumor cells exposed to hypoxia. Doxorubicin 53-56 TNF superfamily member 10 Homo sapiens 86-91 20482316-7 2010 These results indicate that combination of cathepsin E and doxorubicin is sufficient to overcome resistance to TRAIL-mediated apoptosis in chemoresistant prostate cancer PPC-1 cells, thus indicating therapeutic potential for clinical use. Doxorubicin 59-70 TNF superfamily member 10 Homo sapiens 111-116 20014456-8 2009 Apoptosis resistance towards TRAIL could be considerably reduced by adding the chemotherapeutic drugs 5-fluorouracil and doxorubicin as well as the kinase inhibitors LY294002 [inhibition of phosphoinositol-3-kinase (PI3K)], AG1478 (epidermal growth factor receptor kinase), PD98059 (MEK1), rapamycin (mammalian target of rapamycin) and the multi-kinase inhibitor Sorafenib. Doxorubicin 121-132 TNF superfamily member 10 Homo sapiens 29-34 20416058-0 2010 Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 92-97 20416058-4 2010 RESULTS: We demonstrated that doxorubicin and etoposide markedly sensitized SCLC cells expressing caspase-8 to apoptotic effects of TRAIL. Doxorubicin 30-41 TNF superfamily member 10 Homo sapiens 132-137 20416058-8 2010 CONCLUSIONS: Our results highlight significant applicability of doxorubicin and etoposide in sensitization of SCLC cells expressing caspase-8 to treatment with TRAIL. Doxorubicin 64-75 TNF superfamily member 10 Homo sapiens 160-165 20663232-7 2010 Moreover, TRAIL inhibited P-gp efflux function via caspase-3-dependent degradation of P-gp as well as DNA-PKcs and subsequently sensitized MDR cells to MDR-related drugs such as vinblastine and doxorubicin. Doxorubicin 194-205 TNF superfamily member 10 Homo sapiens 10-15 19738990-7 2009 A subtoxic concentration of ADM (0.5 microg/mL) combined with 0.1, 1, or 10 microg/mL TRAIL had a synergistic cytotoxic effect on MCF-7 cells, which was more marked with the combination of TRAIL (0.1 microg/mL) and ADM (0.5 microg/mL). Doxorubicin 28-31 TNF superfamily member 10 Homo sapiens 189-194 19731037-0 2009 Conjugation of doxorubicin to cell penetrating peptides sensitizes human breast MDA-MB 231 cancer cells to endogenous TRAIL-induced apoptosis. Doxorubicin 15-26 TNF superfamily member 10 Homo sapiens 118-123 19731037-3 2009 In this study, we demonstrate that both Dox and Dox-CPPs can increase the density of the TRAIL receptors DR4 and DR5 at the plasma membrane and moderately sensitize MDA-MB 231 cells to exogeneously added recombinant TRAIL, as has already been shown for other chemotherapeutic drugs. Doxorubicin 40-43 TNF superfamily member 10 Homo sapiens 89-94 19731037-3 2009 In this study, we demonstrate that both Dox and Dox-CPPs can increase the density of the TRAIL receptors DR4 and DR5 at the plasma membrane and moderately sensitize MDA-MB 231 cells to exogeneously added recombinant TRAIL, as has already been shown for other chemotherapeutic drugs. Doxorubicin 40-43 TNF superfamily member 10 Homo sapiens 216-221 19731037-4 2009 Moreover, we show that Dox-CPPs, used alone, induce the clustering of TRAIL receptors into ceramide-enriched membrane lipid rafts, a property not shared by unconjugated Dox and that this process is due to the generation of ceramide during Dox-CPPs treatment. Doxorubicin 23-26 TNF superfamily member 10 Homo sapiens 70-75 19731037-6 2009 The capacity of Dox-CPPs to sensitize cancer cells to physiologic amounts of TRAIL suggests that, in addition to their efficiency in combination chemotherapy, these compounds might increase the response of tumor cells to cytotoxic lymphocyte-mediated killing via TRAIL. Doxorubicin 16-19 TNF superfamily member 10 Homo sapiens 77-82 19731037-6 2009 The capacity of Dox-CPPs to sensitize cancer cells to physiologic amounts of TRAIL suggests that, in addition to their efficiency in combination chemotherapy, these compounds might increase the response of tumor cells to cytotoxic lymphocyte-mediated killing via TRAIL. Doxorubicin 16-19 TNF superfamily member 10 Homo sapiens 263-268 19843632-9 2009 Furthermore, we showed that acquired TRAIL resistance was effectively eliminated by combination with etoposide, doxorubicin, or paclitaxel. Doxorubicin 112-123 TNF superfamily member 10 Homo sapiens 37-42 19738990-7 2009 A subtoxic concentration of ADM (0.5 microg/mL) combined with 0.1, 1, or 10 microg/mL TRAIL had a synergistic cytotoxic effect on MCF-7 cells, which was more marked with the combination of TRAIL (0.1 microg/mL) and ADM (0.5 microg/mL). Doxorubicin 215-218 TNF superfamily member 10 Homo sapiens 86-91 17283156-0 2007 Evidence that tumor necrosis factor-related apoptosis-inducing ligand induction by 5-Aza-2"-deoxycytidine sensitizes human breast cancer cells to adriamycin. Doxorubicin 146-156 TNF superfamily member 10 Homo sapiens 14-69 19106633-5 2008 Using HCT116 cells, gene silencing of TNFSF10 by siRNA suppressed caspase 3 and 7 activity, even after treatment with the DNA-damaging chemotherapeutic agent adriamycin. Doxorubicin 158-168 TNF superfamily member 10 Homo sapiens 38-45 19106633-6 2008 TRAIL protein expression was elevated in adriamycin-treated breast cancer cells. Doxorubicin 41-51 TNF superfamily member 10 Homo sapiens 0-5 17922852-0 2007 Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Doxorubicin 22-33 TNF superfamily member 10 Homo sapiens 73-128 17922852-0 2007 Low concentrations of doxorubicin sensitizes human solid cancer cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-receptor (R) 2-mediated apoptosis by inducing TRAIL-R2 expression. Doxorubicin 22-33 TNF superfamily member 10 Homo sapiens 130-135 18006836-0 2007 Silencing of prion protein sensitizes breast adriamycin-resistant carcinoma cells to TRAIL-mediated cell death. Doxorubicin 45-55 TNF superfamily member 10 Homo sapiens 85-90 18006836-4 2007 Down-regulation of PrPc by small interfering RNA increased the sensitivity of Adriamycin- and TRAIL-resistant cells to TRAIL, but not to epirubicin/Adriamycin. Doxorubicin 78-88 TNF superfamily member 10 Homo sapiens 119-124 17893044-1 2007 We have previously shown that doxorubicin sensitizes prostate cancer cells to tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Doxorubicin 30-41 TNF superfamily member 10 Homo sapiens 78-133 17893044-1 2007 We have previously shown that doxorubicin sensitizes prostate cancer cells to tumor-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Doxorubicin 30-41 TNF superfamily member 10 Homo sapiens 135-140 17893044-8 2007 The doxorubicin-mediated decrease in cFLIP(S) and XIAP and the TRAIL-induced apoptosis were prevented by pretreatment with an iron chelator, indicating that expression of these proteins was affected by free radical generation upon interaction of iron with doxorubicin. Doxorubicin 4-15 TNF superfamily member 10 Homo sapiens 63-68 17893044-8 2007 The doxorubicin-mediated decrease in cFLIP(S) and XIAP and the TRAIL-induced apoptosis were prevented by pretreatment with an iron chelator, indicating that expression of these proteins was affected by free radical generation upon interaction of iron with doxorubicin. Doxorubicin 256-267 TNF superfamily member 10 Homo sapiens 63-68 17520194-0 2007 Doxorubicin enhances TRAIL-induced cell death via ceramide-enriched membrane platforms. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 21-26 19625063-8 2009 Chemotherapy with doxorubicin or cisplatin (Ben Venue Laboratories, Bedford, Ohio) decreased the expression of the anti-apoptotic protein cFLIP(S) and increased caspase-8 cleavage, reversing TRAIL resistance in T24 cells. Doxorubicin 18-29 TNF superfamily member 10 Homo sapiens 191-196 18701496-3 2008 Induction of TRAIL by the HDAC inhibitor MS275 can be enhanced by Adriamycin. Doxorubicin 66-76 TNF superfamily member 10 Homo sapiens 13-18 18701496-4 2008 Using different reporter constructs in conjunction with transcription activity assays and chromatin immunoprecipitation assays, we provide evidence that the transcription factor Sp1 is responsible for TRAIL induction by MS275 alone or in combination with Adriamycin. Doxorubicin 255-265 TNF superfamily member 10 Homo sapiens 201-206 18701496-6 2008 Down-regulation of TRAIL by small interfering RNA silencing decreased MS275-mediated Adriamycin-induced caspase activation and apoptosis, thus conferring Adriamycin resistance. Doxorubicin 85-95 TNF superfamily member 10 Homo sapiens 19-24 18701496-6 2008 Down-regulation of TRAIL by small interfering RNA silencing decreased MS275-mediated Adriamycin-induced caspase activation and apoptosis, thus conferring Adriamycin resistance. Doxorubicin 154-164 TNF superfamily member 10 Homo sapiens 19-24 18701496-8 2008 Taken together, our results indicate that induction of TRAIL by the combined treatments with MS275 and Adriamycin is mediated by Sp1 and suggest that transcription factor Sp1 is an important target for the development of novel anticancer agents. Doxorubicin 103-113 TNF superfamily member 10 Homo sapiens 55-60 17376311-11 2007 In OS-732 cells, DOX and CDDP cooperated synergistically with TRAIL when incubated the cells with them for 24 hours (the combined inhibitory rate is (58.360 +/- 2.146)% and (54.101 +/- 2.721)%, respectively). Doxorubicin 17-20 TNF superfamily member 10 Homo sapiens 62-67 17376311-15 2007 DOX and CDDP sensitize osteosarcoma OS-732 cells to TRAIL-induced apoptosis. Doxorubicin 0-3 TNF superfamily member 10 Homo sapiens 52-57 17283156-7 2007 More importantly, down-regulation of TRAIL by small interference RNA silencing decreased 5-aza-CdR-mediated Adriamycin-induced caspase activation and apoptosis, thus conferring Adriamycin resistance. Doxorubicin 108-118 TNF superfamily member 10 Homo sapiens 37-42 17283156-7 2007 More importantly, down-regulation of TRAIL by small interference RNA silencing decreased 5-aza-CdR-mediated Adriamycin-induced caspase activation and apoptosis, thus conferring Adriamycin resistance. Doxorubicin 177-187 TNF superfamily member 10 Homo sapiens 37-42 17283156-8 2007 Taken together, our results suggest that induction of TRAIL by 5-aza-CdR is critical for enhancing chemosensitivity of breast cancer cells to Adriamycin. Doxorubicin 142-152 TNF superfamily member 10 Homo sapiens 54-59 16923369-10 2006 The early apoptosis rates of the adriamycin /etoposide + IFNgamma+TRAIL groups [(17.9 +/- 3.6)%, (14.8 +/- 3.3)%] were higher than that of the IFNgamma+TRAIL group [(3.9 +/- 1.2)% ](F=26.233, P < 0.01). Doxorubicin 33-43 TNF superfamily member 10 Homo sapiens 152-157 17649723-0 2007 [Study of molecular mechanism of doxorubicin enhancement of TRAIL, inducing apoptosis of myeloma cell line KM3]. Doxorubicin 33-44 TNF superfamily member 10 Homo sapiens 60-65 17649723-1 2007 OBJECTIVE: To investigate the molecular mechanism of doxorubicin enhancement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducing apoptotic effect on multiple myeloma cell line KM3. Doxorubicin 53-64 TNF superfamily member 10 Homo sapiens 80-135 17649723-1 2007 OBJECTIVE: To investigate the molecular mechanism of doxorubicin enhancement of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) inducing apoptotic effect on multiple myeloma cell line KM3. Doxorubicin 53-64 TNF superfamily member 10 Homo sapiens 137-142 17649723-4 2007 RESULTS: The apoptosis ratio of KM3 cells was 20.88%, 40.03%, 57.87%, 60.82% respectively when treated with different concentration of TRAIL (10, 20, 50, 100 ng/ml) combining with doxorubicin. Doxorubicin 180-191 TNF superfamily member 10 Homo sapiens 135-140 17649723-6 2007 DR5 expression increased while P65 decreased as the doses of doxorubicin increased when KM3 cells treated with doxorubicin (0.5, 1.0, 2.0 and 4.0 microg/ml) plus 20 ng/ml TRAIL. Doxorubicin 61-72 TNF superfamily member 10 Homo sapiens 171-176 17649723-7 2007 CONCLUSION: Increasing the expression of DR5 and nuclear transferring of P65 are the important molecular mechanism by which doxorubicin enhances TRAIL-inducing apoptosis of KM3 cells. Doxorubicin 124-135 TNF superfamily member 10 Homo sapiens 145-150 17106251-3 2006 However, sensitivity to TRAIL is enhanced by doxorubicin, which correlated with a decrease in expression of the caspase-8 inhibitor cFLIP (Kelly et al., Cancer Biol Ther 1:520). Doxorubicin 45-56 TNF superfamily member 10 Homo sapiens 24-29 17106251-8 2006 We conclude that doxorubicin-mediated downregulation of cFLIPS, which occurs at the post-transcriptional level independent of proteasome-mediated pathways, is sufficient to enhance TRAIL sensitivity in PC3 prostate carcinoma cells. Doxorubicin 17-28 TNF superfamily member 10 Homo sapiens 181-186 17047073-7 2006 Importantly, down-regulation of TRAIL by small interfering RNA silencing decreased TNFalpha-mediated Adriamycin-induced caspase activation and apoptosis, and thus enhanced breast cancer cell resistance to Adriamycin. Doxorubicin 101-111 TNF superfamily member 10 Homo sapiens 32-37 17047073-7 2006 Importantly, down-regulation of TRAIL by small interfering RNA silencing decreased TNFalpha-mediated Adriamycin-induced caspase activation and apoptosis, and thus enhanced breast cancer cell resistance to Adriamycin. Doxorubicin 205-215 TNF superfamily member 10 Homo sapiens 32-37 16098063-0 2005 Activity of selective fully human agonistic antibodies to the TRAIL death receptors TRAIL-R1 and TRAIL-R2 in primary and cultured lymphoma cells: induction of apoptosis and enhancement of doxorubicin- and bortezomib-induced cell death. Doxorubicin 188-199 TNF superfamily member 10 Homo sapiens 62-67 16428504-11 2006 Furthermore, 17-AAG depleted cellular contents of Akt, decreased extracellular signal-regulated kinase (ERK) phosphorylation, and reduced cellular FLICE-like inhibitory protein levels (FLIP), and thus enhanced the cytotoxic effect of doxorubicin and agonistic anti-tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor antibodies. Doxorubicin 234-245 TNF superfamily member 10 Homo sapiens 260-320 16428504-11 2006 Furthermore, 17-AAG depleted cellular contents of Akt, decreased extracellular signal-regulated kinase (ERK) phosphorylation, and reduced cellular FLICE-like inhibitory protein levels (FLIP), and thus enhanced the cytotoxic effect of doxorubicin and agonistic anti-tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) death receptor antibodies. Doxorubicin 234-245 TNF superfamily member 10 Homo sapiens 322-327 16327988-4 2006 however, the genotoxic drugs, Doxorubicin and Cisplatin, are able to sensitize U2OS cells to TRAIL, without affecting their surface expression of either death or decoy TRAIL receptors. Doxorubicin 30-41 TNF superfamily member 10 Homo sapiens 93-98 16619517-1 2006 BACKGROUND: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in combination with a chemotherapeutic agent, cis-diammine dichloroplatinum (CDDP) or doxorubicin (DXR), has recently been demonstrated to result in enhanced apoptotic cell death in the sarcoma cell lines MG-63 and SaOS-2. Doxorubicin 168-179 TNF superfamily member 10 Homo sapiens 75-80 16619517-1 2006 BACKGROUND: Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) in combination with a chemotherapeutic agent, cis-diammine dichloroplatinum (CDDP) or doxorubicin (DXR), has recently been demonstrated to result in enhanced apoptotic cell death in the sarcoma cell lines MG-63 and SaOS-2. Doxorubicin 181-184 TNF superfamily member 10 Homo sapiens 75-80 15809718-6 2005 TRAIL expression on tumor cells was detected by flow cytometry and was dramatically induced after the addition of doxorubicin, a chemotherapeutic agent, or cytokine stimulation with TNF-alpha, IL-1beta or IL-18. Doxorubicin 114-125 TNF superfamily member 10 Homo sapiens 0-5 15067350-8 2004 In contrast, the combination of Apo2L/TRAIL and chemotherapeutic drugs produced a significant increase in tumour cell death, with DOX and Apo2L/TRAIL proving to be the most effective combination. Doxorubicin 130-133 TNF superfamily member 10 Homo sapiens 32-37 15897917-0 2005 Subtoxic concentration of doxorubicin enhances TRAIL-induced apoptosis in human prostate cancer cell line LNCaP. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 47-52 15897917-3 2005 In this study, human prostatic cancer cell line LNCaP was found to be resistant to TRAIL-induced apoptosis while it could be restored to TRAIL sensitivity with combination treatment of low concentration of doxorubicin. Doxorubicin 206-217 TNF superfamily member 10 Homo sapiens 83-88 15897917-3 2005 In this study, human prostatic cancer cell line LNCaP was found to be resistant to TRAIL-induced apoptosis while it could be restored to TRAIL sensitivity with combination treatment of low concentration of doxorubicin. Doxorubicin 206-217 TNF superfamily member 10 Homo sapiens 137-142 15897917-4 2005 TRAIL receptor-1 (DR4) and TRAIL receptor-2 (DR5) were upregulated under the treatment of doxorubicin and verified to be responsible for TRAIL-mediated signal transduction. Doxorubicin 90-101 TNF superfamily member 10 Homo sapiens 0-5 15897917-4 2005 TRAIL receptor-1 (DR4) and TRAIL receptor-2 (DR5) were upregulated under the treatment of doxorubicin and verified to be responsible for TRAIL-mediated signal transduction. Doxorubicin 90-101 TNF superfamily member 10 Homo sapiens 27-32 15897917-8 2005 Subtoxic concentration of doxorubicin effectively boosted TRAIL sensitivity via depletion of antiapoptotic protein. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 58-63 15289869-0 2004 Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 24-29 15289869-0 2004 Doxorubicin potentiates TRAIL cytotoxicity and apoptosis and can overcome TRAIL-resistance in rhabdomyosarcoma cells. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 74-79 15289869-14 2004 DOX plus TRAIL-induced more cytotoxicity and apoptosis in all cell lines compared to TRAIL alone. Doxorubicin 0-3 TNF superfamily member 10 Homo sapiens 85-90 15289869-15 2004 In 37B8R, DOX overcame resistance to TRAIL. Doxorubicin 10-13 TNF superfamily member 10 Homo sapiens 37-42 15289869-18 2004 DOX with TRAIL could overcome TRAIL-resistance in 37B8R cells. Doxorubicin 0-3 TNF superfamily member 10 Homo sapiens 9-14 15289869-18 2004 DOX with TRAIL could overcome TRAIL-resistance in 37B8R cells. Doxorubicin 0-3 TNF superfamily member 10 Homo sapiens 30-35 15329202-5 2004 Treated with TRAIL combination with ADM (0.1 mg/L), it showed significant inhibitory effect on the growth of HepG2/ADM, the percentage of apoptosis was increased as comparison with control at 24 h. CONCLUSION: MDR1 might not take part in resistance to TRAIL-induced apoptosis. Doxorubicin 36-39 TNF superfamily member 10 Homo sapiens 13-18 15329202-5 2004 Treated with TRAIL combination with ADM (0.1 mg/L), it showed significant inhibitory effect on the growth of HepG2/ADM, the percentage of apoptosis was increased as comparison with control at 24 h. CONCLUSION: MDR1 might not take part in resistance to TRAIL-induced apoptosis. Doxorubicin 36-39 TNF superfamily member 10 Homo sapiens 252-257 15781649-8 2005 The knockdown of the predominant Bcl-XL overexpression significantly reduces the viability of pancreatic cancer cells to TNFalpha- and TRAIL-mediated apoptosis by sublethal-dose single and combined antitumor drugs, including geldanamycin, PS-341, Trichostatin A, and doxorubicine. Doxorubicin 267-279 TNF superfamily member 10 Homo sapiens 135-140 15067350-8 2004 In contrast, the combination of Apo2L/TRAIL and chemotherapeutic drugs produced a significant increase in tumour cell death, with DOX and Apo2L/TRAIL proving to be the most effective combination. Doxorubicin 130-133 TNF superfamily member 10 Homo sapiens 38-43 12838325-7 2003 Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5. Doxorubicin 75-86 TNF superfamily member 10 Homo sapiens 139-144 15110186-4 2004 Studies from our laboratory have also shown that TRAIL-resistant renal cell carcinoma, prostate gland cancer, and bladder cancer cells are sensitized by subtoxic concentrations of chemotherapeutic drugs including doxorubicin, epirubicin, pirarubicin, and cisplatin. Doxorubicin 213-224 TNF superfamily member 10 Homo sapiens 49-54 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Doxorubicin 33-36 TNF superfamily member 10 Homo sapiens 151-156 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Doxorubicin 33-36 TNF superfamily member 10 Homo sapiens 157-162 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Doxorubicin 33-36 TNF superfamily member 10 Homo sapiens 222-227 14601052-3 2003 Here, we report that while ActD, DOX and CDDP sensitised both OS and Ewing"s tumour cell lines and normal cells (hOBs, synovial cells, fibroblasts) to TRAIL/Apo2L-induced apoptosis, the combination of etoposide (VP16) and TRAIL/Apo2L was selectively active on tumour cells without affecting normal cells. Doxorubicin 33-36 TNF superfamily member 10 Homo sapiens 228-233 14500373-4 2003 The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Doxorubicin 95-105 TNF superfamily member 10 Homo sapiens 137-142 14500373-4 2003 The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Doxorubicin 95-105 TNF superfamily member 10 Homo sapiens 162-167 14500373-4 2003 The chemotherapeutic drugs (paclitaxel, vincristine, vinblastine, etoposide, camptothecin, and Adriamycin) induced death receptors (DRs) TRAIL receptor 1/DR4 and TRAIL receptor 2/DR5, and successive treatment with TRAIL resulted in apoptosis of both TRAIL-sensitive and -resistant cells. Doxorubicin 95-105 TNF superfamily member 10 Homo sapiens 162-167 14500373-6 2003 TRAIL induces apoptosis in Adriamycin-resistant MCF7 cells already expressing high levels of death receptors DR4 and DR5. Doxorubicin 27-37 TNF superfamily member 10 Homo sapiens 0-5 12919886-5 2003 Pretreatment with sub-toxic or slightly toxic concentrations of chemotherapeutic agents (cis-diammine dichloroplatinum, CDDP and doxorubicin, DXR) sensitized both cell lines to TRAIL-induced apoptosis, as assessed by the propidium iodide or Annexin V-Cy5 staining method. Doxorubicin 129-140 TNF superfamily member 10 Homo sapiens 177-182 15067350-9 2004 These data suggest the potential for Apo2L/TRAIL to increase the effectiveness of chemotherapeutic drugs in bone and soft tissue sarcomas, while perhaps concurrently allowing a reduction in the exposure to drugs such as DOX, and a consequent reduction in toxicity. Doxorubicin 220-223 TNF superfamily member 10 Homo sapiens 37-42 15067350-9 2004 These data suggest the potential for Apo2L/TRAIL to increase the effectiveness of chemotherapeutic drugs in bone and soft tissue sarcomas, while perhaps concurrently allowing a reduction in the exposure to drugs such as DOX, and a consequent reduction in toxicity. Doxorubicin 220-223 TNF superfamily member 10 Homo sapiens 43-48 15033719-8 2003 Interestingly, the apoptotic response to TRAIL was enhanced by co-treatment of SH-EP and IGR-N91-C8 cells with CHX or with sub-toxic concentration of doxorubicin (DOX) in a caspase-dependent manner, as cells could be protected from death by specific caspase-8 or pan-caspase inhibitors. Doxorubicin 150-161 TNF superfamily member 10 Homo sapiens 41-46 15033719-8 2003 Interestingly, the apoptotic response to TRAIL was enhanced by co-treatment of SH-EP and IGR-N91-C8 cells with CHX or with sub-toxic concentration of doxorubicin (DOX) in a caspase-dependent manner, as cells could be protected from death by specific caspase-8 or pan-caspase inhibitors. Doxorubicin 163-166 TNF superfamily member 10 Homo sapiens 41-46 15033719-9 2003 CHX or DOX was shown to enhance TRAIL-induced caspase-8 activation and loss of mitochondrial transmembrane potential. Doxorubicin 7-10 TNF superfamily member 10 Homo sapiens 32-37 15033719-11 2003 Moreover, DOX and CHX were able to sensitize NB cell lines to TRAIL-induced apoptosis in a caspase-8-dependent manner by engaging death receptor and mitochondrial signaling pathways. Doxorubicin 10-13 TNF superfamily member 10 Homo sapiens 62-67 12904602-7 2003 We examined the effect of doxorubicin on the expression levels of TRAIL receptors and its enhancement on the susceptibility of MRT cell lines to TRAIL. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 66-71 12904602-7 2003 We examined the effect of doxorubicin on the expression levels of TRAIL receptors and its enhancement on the susceptibility of MRT cell lines to TRAIL. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 145-150 12904602-9 2003 Moreover, doxorubicin, NF-kappaB inhibitor (SN50), and PI3-kinase/Akt inhibitor (wortmannin, LY294002) enhanced the susceptibility of MRT cell lines to TRAIL/Apo2L-induced apoptosis. Doxorubicin 10-21 TNF superfamily member 10 Homo sapiens 152-157 12904602-9 2003 Moreover, doxorubicin, NF-kappaB inhibitor (SN50), and PI3-kinase/Akt inhibitor (wortmannin, LY294002) enhanced the susceptibility of MRT cell lines to TRAIL/Apo2L-induced apoptosis. Doxorubicin 10-21 TNF superfamily member 10 Homo sapiens 158-163 12946317-5 2003 An in vivo study showed that aerosolized administration of an adenovector expressing the GFP-TRAIL fusion protein from the human telomerase reverse transcriptase promoter (designated Ad/gTRAIL) also decreased the number of lung metastases from both doxorubicin-sensitive and doxorubicin-resistant breast cancer cell lines. Doxorubicin 249-260 TNF superfamily member 10 Homo sapiens 93-98 12946317-5 2003 An in vivo study showed that aerosolized administration of an adenovector expressing the GFP-TRAIL fusion protein from the human telomerase reverse transcriptase promoter (designated Ad/gTRAIL) also decreased the number of lung metastases from both doxorubicin-sensitive and doxorubicin-resistant breast cancer cell lines. Doxorubicin 275-286 TNF superfamily member 10 Homo sapiens 93-98 12838325-7 2003 Importantly, treatment of resistant cells with the chemotherapeutic agents doxorubicin, cisplatin and etoposide reversed the resistance to Apo2L/TRAIL, which was associated with drug-induced upregulation of mRNA encoding the death receptors DR4 and DR5. Doxorubicin 75-86 TNF superfamily member 10 Homo sapiens 145-150 12926060-3 2003 MATERIALS AND METHODS: Both TRAIL-sensitive 8226 and -resistant MG-63 cells were pretreated with the anti-tumor agent doxorubicin or cisplatin for 24 hours, washed and then exposed to retroviral transduction with TRAIL for a further 24 hours, followed by assay for cell survival using a WST-8 kit. Doxorubicin 118-129 TNF superfamily member 10 Homo sapiens 28-33 12926060-4 2003 RESULTS: Doxorubicin or cisplatin sensitized both RPMI-8226 and MG-63 cells to TRAIL-induced death in a synergistic manner. Doxorubicin 9-20 TNF superfamily member 10 Homo sapiens 79-84 12835727-3 2003 The Jurkat cell line was TRAIL sensitive and TRAIL-resistant Molt-4 cell line became sensitive after being treated with TRAIL and a low dose of doxorubicin (0.1 micro M), but UCB mononuclear cells remained resistant. Doxorubicin 144-155 TNF superfamily member 10 Homo sapiens 25-30 12835727-3 2003 The Jurkat cell line was TRAIL sensitive and TRAIL-resistant Molt-4 cell line became sensitive after being treated with TRAIL and a low dose of doxorubicin (0.1 micro M), but UCB mononuclear cells remained resistant. Doxorubicin 144-155 TNF superfamily member 10 Homo sapiens 45-50 12835727-3 2003 The Jurkat cell line was TRAIL sensitive and TRAIL-resistant Molt-4 cell line became sensitive after being treated with TRAIL and a low dose of doxorubicin (0.1 micro M), but UCB mononuclear cells remained resistant. Doxorubicin 144-155 TNF superfamily member 10 Homo sapiens 45-50 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 160-171 TNF superfamily member 10 Homo sapiens 3-8 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 160-171 TNF superfamily member 10 Homo sapiens 75-80 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 160-171 TNF superfamily member 10 Homo sapiens 75-80 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 160-171 TNF superfamily member 10 Homo sapiens 75-80 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 200-211 TNF superfamily member 10 Homo sapiens 3-8 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 200-211 TNF superfamily member 10 Homo sapiens 75-80 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 200-211 TNF superfamily member 10 Homo sapiens 75-80 12835727-5 2003 In TRAIL-sensitive Jurkat cells, caspases 8, 9, 3, and 7 were activated by TRAIL treatment and activation of caspases was augmented by TRAIL plus a low dose of doxorubicin than TRAIL or a low dose of doxorubicin alone in Molt-4 cells. Doxorubicin 200-211 TNF superfamily member 10 Homo sapiens 75-80 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 67-72 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 67-72 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 67-72 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 26-37 TNF superfamily member 10 Homo sapiens 67-72 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 113-124 TNF superfamily member 10 Homo sapiens 16-21 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 113-124 TNF superfamily member 10 Homo sapiens 67-72 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 113-124 TNF superfamily member 10 Homo sapiens 67-72 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 113-124 TNF superfamily member 10 Homo sapiens 67-72 12763223-6 2003 Coincubation of TRAIL and doxorubicin led to the overexpression of TRAIL-R2 resulting in a synergistic effect of doxorubicin and TRAIL in TRAIL-sensitive cell lines and in the overcoming of TRAIL-resistance in all of the TRAIL-resistant cell lines, except HTB-91, which lacked caspase 8 expression. Doxorubicin 113-124 TNF superfamily member 10 Homo sapiens 67-72 12610517-6 2003 We show that genotoxic agents such as cisplatin, doxorubicin and camptothecin, in addition to UV radiation, can induce TRAIL-R2 on the cell surface of TRAIL receptor-negative tumour cells. Doxorubicin 49-60 TNF superfamily member 10 Homo sapiens 119-124 12584736-0 2003 Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Doxorubicin 49-59 TNF superfamily member 10 Homo sapiens 15-20 12584736-0 2003 Enhancement of TRAIL/Apo2L-mediated apoptosis by adriamycin through inducing DR4 and DR5 in renal cell carcinoma cells. Doxorubicin 49-59 TNF superfamily member 10 Homo sapiens 21-26 12660816-5 2003 Clinically relevant concentrations of cisplatin, doxorubicin and 5-fluorouracil synergize with TRAIL to trigger HT-29 cell death. Doxorubicin 49-60 TNF superfamily member 10 Homo sapiens 95-100 12800232-5 2003 The present study was to investigate the cell killing action of TRAIL on colon cancer cell line SW480, its synergistic effect with doxorubicin, and the possible mechanisms. Doxorubicin 131-142 TNF superfamily member 10 Homo sapiens 64-69 12800232-12 2003 (3) TRAIL could synergize with doxorubicin to kill SW480 cells effectively, which was represented by the boosted killing effect of doxorubicin on theses cells. Doxorubicin 31-42 TNF superfamily member 10 Homo sapiens 4-9 12800232-12 2003 (3) TRAIL could synergize with doxorubicin to kill SW480 cells effectively, which was represented by the boosted killing effect of doxorubicin on theses cells. Doxorubicin 131-142 TNF superfamily member 10 Homo sapiens 4-9 12800232-13 2003 IC(50) of doxorubicin against SW480 cells sharply reduced when it was combined with TRAIL. Doxorubicin 10-21 TNF superfamily member 10 Homo sapiens 84-89 12800232-19 2003 CONCLUSION: SW480 cells are not sensitive to TRAIL, but TRAIL can synergize with lower concentration of doxorubicin to induce apoptosis effectively. Doxorubicin 104-115 TNF superfamily member 10 Homo sapiens 56-61 12398939-9 2002 In contrast, the human osteogenic sarcoma cell lines, BTK-143 and G-292, were sensitive to exogenous Apo2L/TRAIL alone, and to the combined effect of Apo2L/TRAIL/cisplatin and Apo2L/TRAIL/doxorubicin treatments, respectively. Doxorubicin 188-199 TNF superfamily member 10 Homo sapiens 101-106 12439752-3 2002 Furthermore, treatment with Ad/gTRAIL was effective in killing breast cancer lines resistant to doxorubicin or soluble TRAIL protein. Doxorubicin 96-107 TNF superfamily member 10 Homo sapiens 32-37 12398939-9 2002 In contrast, the human osteogenic sarcoma cell lines, BTK-143 and G-292, were sensitive to exogenous Apo2L/TRAIL alone, and to the combined effect of Apo2L/TRAIL/cisplatin and Apo2L/TRAIL/doxorubicin treatments, respectively. Doxorubicin 188-199 TNF superfamily member 10 Homo sapiens 150-155 12398939-9 2002 In contrast, the human osteogenic sarcoma cell lines, BTK-143 and G-292, were sensitive to exogenous Apo2L/TRAIL alone, and to the combined effect of Apo2L/TRAIL/cisplatin and Apo2L/TRAIL/doxorubicin treatments, respectively. Doxorubicin 188-199 TNF superfamily member 10 Homo sapiens 150-155 11956588-0 2002 Doxorubicin enhances TRAIL-induced apoptosis in prostate cancer. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 21-26 12496481-0 2002 Doxorubicin pretreatment sensitizes prostate cancer cell lines to TRAIL induced apoptosis which correlates with the loss of c-FLIP expression. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 66-71 12496481-1 2002 Tumor necrosis factor-related apoptosis inducing ligand (TRAIL/Apo2L) can induce receptor-mediated apoptosis in prostate cancer cell lines that have been co-treated with the chemotherapeutic agent doxorubicin (Voelkel-Johnson C, et al. Doxorubicin 197-208 TNF superfamily member 10 Homo sapiens 57-62 12496481-1 2002 Tumor necrosis factor-related apoptosis inducing ligand (TRAIL/Apo2L) can induce receptor-mediated apoptosis in prostate cancer cell lines that have been co-treated with the chemotherapeutic agent doxorubicin (Voelkel-Johnson C, et al. Doxorubicin 197-208 TNF superfamily member 10 Homo sapiens 63-68 12496481-3 2002 In this study, we report that pretreatment with doxorubicin is sufficient to sensitize cells to TRAIL. Doxorubicin 48-59 TNF superfamily member 10 Homo sapiens 96-101 12496481-6 2002 TRAIL receptor mRNAs (DR4, DR5, and DcR2) were induced by doxorubicin but these changes were not reflected at the protein level. Doxorubicin 58-69 TNF superfamily member 10 Homo sapiens 0-5 12496481-11 2002 Therefore, our results suggest that doxorubicin- mediated down regulation of c-FLIP(S) predisposes cells to TRAIL-induced apoptosis. Doxorubicin 36-47 TNF superfamily member 10 Homo sapiens 108-113 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 133-144 TNF superfamily member 10 Homo sapiens 13-18 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 133-144 TNF superfamily member 10 Homo sapiens 19-24 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 133-144 TNF superfamily member 10 Homo sapiens 61-66 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 133-144 TNF superfamily member 10 Homo sapiens 67-72 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 146-149 TNF superfamily member 10 Homo sapiens 13-18 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 146-149 TNF superfamily member 10 Homo sapiens 19-24 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 146-149 TNF superfamily member 10 Homo sapiens 61-66 11992538-6 2002 In contrast, Apo2L/TRAIL-resistant cells were susceptible to Apo2L/TRAIL-mediated apoptosis in the presence of the anticancer drugs, Doxorubicin (DOX), Cisplatin (CDDP) and Etoposide (ETP) but not Methotrexate (MTX) or Cyclophosphamide (CPM). Doxorubicin 146-149 TNF superfamily member 10 Homo sapiens 67-72 11956588-2 2002 The anthracycline doxorubicin (DOX) can sensitize several types of cancer cells to TRAIL-mediated apoptosis. Doxorubicin 18-29 TNF superfamily member 10 Homo sapiens 83-88 11956588-2 2002 The anthracycline doxorubicin (DOX) can sensitize several types of cancer cells to TRAIL-mediated apoptosis. Doxorubicin 31-34 TNF superfamily member 10 Homo sapiens 83-88 11956588-3 2002 Here we report that DOX enhances TRAIL-induced apoptosis and cytotoxicity against prostate cancer cells. Doxorubicin 20-23 TNF superfamily member 10 Homo sapiens 33-38 11956588-12 2002 These findings indicate that DOX enhances TRAIL-induced apoptosis and cytotoxicity in prostate cancer by activation of caspase cascades, and suggest that TRAIL in combination with DOX have a therapeutic potential in the treatment of prostate cancer. Doxorubicin 29-32 TNF superfamily member 10 Homo sapiens 42-47 11956588-12 2002 These findings indicate that DOX enhances TRAIL-induced apoptosis and cytotoxicity in prostate cancer by activation of caspase cascades, and suggest that TRAIL in combination with DOX have a therapeutic potential in the treatment of prostate cancer. Doxorubicin 29-32 TNF superfamily member 10 Homo sapiens 154-159 11956588-12 2002 These findings indicate that DOX enhances TRAIL-induced apoptosis and cytotoxicity in prostate cancer by activation of caspase cascades, and suggest that TRAIL in combination with DOX have a therapeutic potential in the treatment of prostate cancer. Doxorubicin 180-183 TNF superfamily member 10 Homo sapiens 42-47 12014636-4 2002 RESULTS: Treatment with suboptimal concentrations of etoposide or doxorubicin rendered T-47D cells sensitive to anti-Fas antibody or TRAIL, consistent with Fas and TRAIL-R1 mRNA expression by T-47D cells following drug treatment. Doxorubicin 66-77 TNF superfamily member 10 Homo sapiens 133-138 11090076-6 2000 Treatment of human leukemic cells with etoposide, Ara-C, or doxorubicin increased DR5 but not DR4, Fas, DcR1, DcR2, Fas ligand, or Apo-2L levels. Doxorubicin 60-71 TNF superfamily member 10 Homo sapiens 131-137 11857034-0 2002 Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Doxorubicin 118-129 TNF superfamily member 10 Homo sapiens 86-91 11857034-0 2002 Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Doxorubicin 118-129 TNF superfamily member 10 Homo sapiens 92-97 11857034-9 2002 Full-length TRAIL delivered by an adenoviral vector (AdTRAIL-IRES-GFP) killed prostate cancer cell lines and PrEC without requisite doxorubicin cotreatment. Doxorubicin 132-143 TNF superfamily member 10 Homo sapiens 12-17 11803469-2 2002 We demonstrate that in H157 human lung carcinoma cells, etoposide and doxorubicin induce the NF-kappaB-dependent expression of both pro- and anti-apoptotic proteins including TRAIL and its death receptor, DR5, and IAPs. Doxorubicin 70-81 TNF superfamily member 10 Homo sapiens 175-180 12118126-6 2001 In contrast, the addition of TRAIL and drug together produced a significant increase in sarcoma cell apoptosis, with TRAIL and doxorubicin the most effective combination. Doxorubicin 127-138 TNF superfamily member 10 Homo sapiens 29-34 11772267-8 2001 These studies demonstrated that doxorubicin, an agent which is commonly used to treat MM patients, upregulated the expression of the DR5 death-signalling TRAIL receptor and synergistically enhanced the pro-apoptotic effect of TRAIL on MM cells. Doxorubicin 32-43 TNF superfamily member 10 Homo sapiens 154-159 11772267-8 2001 These studies demonstrated that doxorubicin, an agent which is commonly used to treat MM patients, upregulated the expression of the DR5 death-signalling TRAIL receptor and synergistically enhanced the pro-apoptotic effect of TRAIL on MM cells. Doxorubicin 32-43 TNF superfamily member 10 Homo sapiens 226-231 11245478-4 2001 Clinically relevant concentrations of cisplatin and doxorubicin sensitize the most resistant colon cancer cell lines to TRAIL-induced cell death without modifying the expression nor the localization of TRAIL receptors in these cells. Doxorubicin 52-63 TNF superfamily member 10 Homo sapiens 120-125 11751478-0 2001 Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Doxorubicin 0-10 TNF superfamily member 10 Homo sapiens 90-160 11751478-0 2001 Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Doxorubicin 0-10 TNF superfamily member 10 Homo sapiens 162-167 11751478-0 2001 Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Doxorubicin 26-36 TNF superfamily member 10 Homo sapiens 90-160 11751478-0 2001 Adriamycin sensitizes the adriamycin-resistant 8226/Dox40 human multiple myeloma cells to Apo2L/tumor necrosis factor-related apoptosis-inducing ligand-mediated (TRAIL) apoptosis. Doxorubicin 26-36 TNF superfamily member 10 Homo sapiens 162-167 11751478-5 2001 This study examined whether an Adriamycin-resistant multiple myeloma (MM) cell line (8226/Dox40) can be sensitized by Adriamycin (ADR) to Apo2L/TRAIL-mediated apoptosis. Doxorubicin 31-41 TNF superfamily member 10 Homo sapiens 138-143 11751478-5 2001 This study examined whether an Adriamycin-resistant multiple myeloma (MM) cell line (8226/Dox40) can be sensitized by Adriamycin (ADR) to Apo2L/TRAIL-mediated apoptosis. Doxorubicin 31-41 TNF superfamily member 10 Homo sapiens 144-149 11751478-7 2001 Adriamycin treatment modestly up-regulated Apo2L/TRAIL-R2 (DR5) and had no effect on the expression of Fas-associated death domain, c-FLIP, Bcl-2, Bcl(xL), Bax, and IAP family members (cIAP-1, cIAP-2, XIAP, and survivin). Doxorubicin 0-10 TNF superfamily member 10 Homo sapiens 43-48 11468181-3 2001 TRAIL/Apo2L potently induced apoptosis of MM cells from patients and the majority of MM cell lines, including cells sensitive or resistant to dexamethasone (Dex), doxorubicin (Dox), melphalan, and mitoxantrone. Doxorubicin 163-174 TNF superfamily member 10 Homo sapiens 0-5 11468181-3 2001 TRAIL/Apo2L potently induced apoptosis of MM cells from patients and the majority of MM cell lines, including cells sensitive or resistant to dexamethasone (Dex), doxorubicin (Dox), melphalan, and mitoxantrone. Doxorubicin 163-174 TNF superfamily member 10 Homo sapiens 6-11 11468181-3 2001 TRAIL/Apo2L potently induced apoptosis of MM cells from patients and the majority of MM cell lines, including cells sensitive or resistant to dexamethasone (Dex), doxorubicin (Dox), melphalan, and mitoxantrone. Doxorubicin 176-179 TNF superfamily member 10 Homo sapiens 0-5 11468181-3 2001 TRAIL/Apo2L potently induced apoptosis of MM cells from patients and the majority of MM cell lines, including cells sensitive or resistant to dexamethasone (Dex), doxorubicin (Dox), melphalan, and mitoxantrone. Doxorubicin 176-179 TNF superfamily member 10 Homo sapiens 6-11 11468181-7 2001 Dox up-regulated the expression of the TRAIL receptor death receptor 5 (DR5) and synergistically enhanced the effect of TRAIL not only against MM cells sensitive to, but also against those resistant to, Dex- or Dox-induced apoptosis. Doxorubicin 0-3 TNF superfamily member 10 Homo sapiens 39-44 11468181-7 2001 Dox up-regulated the expression of the TRAIL receptor death receptor 5 (DR5) and synergistically enhanced the effect of TRAIL not only against MM cells sensitive to, but also against those resistant to, Dex- or Dox-induced apoptosis. Doxorubicin 0-3 TNF superfamily member 10 Homo sapiens 120-125 11468181-7 2001 Dox up-regulated the expression of the TRAIL receptor death receptor 5 (DR5) and synergistically enhanced the effect of TRAIL not only against MM cells sensitive to, but also against those resistant to, Dex- or Dox-induced apoptosis. Doxorubicin 211-214 TNF superfamily member 10 Homo sapiens 39-44 11468181-7 2001 Dox up-regulated the expression of the TRAIL receptor death receptor 5 (DR5) and synergistically enhanced the effect of TRAIL not only against MM cells sensitive to, but also against those resistant to, Dex- or Dox-induced apoptosis. Doxorubicin 211-214 TNF superfamily member 10 Homo sapiens 120-125 11472983-6 2001 TRAIL plus chemotherapy (doxorubicin, cis-platinum, etoposide, or gemcitabine) acted cooperatively to induce apoptosis in mesothelioma cells (M28, REN, VAMT, and MS-1). Doxorubicin 25-36 TNF superfamily member 10 Homo sapiens 0-5 11472983-7 2001 For example, in M28 cells treated for 18 h, apoptosis from TRAIL (100 ng/ml) plus doxorubicin (0.6 microg/ml; 71 +/- 11%) greatly exceeded that from TRAIL alone (21 +/- 8%) or from doxorubicin alone (6 +/- 2%) (means +/- standard deviation; P < 0.03). Doxorubicin 181-192 TNF superfamily member 10 Homo sapiens 59-64 11417478-10 2001 Doxorubicin sensitized four of 35 initially TRAIL-resistant samples and augmented TRAIL-induced apoptosis in two of 14 TRAIL-susceptible samples. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 44-49 11417478-10 2001 Doxorubicin sensitized four of 35 initially TRAIL-resistant samples and augmented TRAIL-induced apoptosis in two of 14 TRAIL-susceptible samples. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 82-87 11417478-10 2001 Doxorubicin sensitized four of 35 initially TRAIL-resistant samples and augmented TRAIL-induced apoptosis in two of 14 TRAIL-susceptible samples. Doxorubicin 0-11 TNF superfamily member 10 Homo sapiens 82-87 11417478-12 2001 The observed sensitization of leukemic cells to TRAIL by doxorubicin in vitro indicates that TRAIL should be further evaluated as to its possible role as an in vivo cotherapeutic in acute leukemia. Doxorubicin 57-68 TNF superfamily member 10 Homo sapiens 48-53 11417478-12 2001 The observed sensitization of leukemic cells to TRAIL by doxorubicin in vitro indicates that TRAIL should be further evaluated as to its possible role as an in vivo cotherapeutic in acute leukemia. Doxorubicin 57-68 TNF superfamily member 10 Homo sapiens 93-98 11090076-8 2000 These findings indicate that treatment with etoposide, Ara-C, or doxorubicin up-regulates DR5 levels in a p53-independent manner and sensitizes human acute leukemia cells to Apo-2L-induced apoptosis. Doxorubicin 65-76 TNF superfamily member 10 Homo sapiens 174-180 10960439-9 2000 In addition, we found that treatment with conventional chemotherapeutic agents, doxorubicin and camptothecin, dramatically augmented TRAIL-induced cytotoxicity in most of the HCC cell lines. Doxorubicin 80-91 TNF superfamily member 10 Homo sapiens 133-138 10690508-10 2000 TRAIL-resistant cells became susceptible to TRAIL-mediated apoptosis in the presence of doxorubicin. Doxorubicin 88-99 TNF superfamily member 10 Homo sapiens 0-5 10690508-10 2000 TRAIL-resistant cells became susceptible to TRAIL-mediated apoptosis in the presence of doxorubicin. Doxorubicin 88-99 TNF superfamily member 10 Homo sapiens 44-49 10690508-11 2000 In TRAIL-sensitive cells, caspases 8, 9, and 3 were activated after TRAIL treatment, but in TRAIL-resistant cells, they were activated only by the combination of TRAIL and doxorubicin. Doxorubicin 172-183 TNF superfamily member 10 Homo sapiens 3-8 10690508-12 2000 Our results suggest: (a) evaluation of tumor DR4 and FLIP expression and host DR4 codon 441 status could be potentially useful predictors of TRAIL sensitivity, and (b) doxorubicin, in combination with TRAIL, may effectively promote caspase activation in TRAIL-resistant tumors. Doxorubicin 168-179 TNF superfamily member 10 Homo sapiens 141-146 10933923-2 2000 We previously identified the death domain containing proapoptotic TRAIL death receptor KILLER/DR5 (TRAIL-R2) as an upregulated transcript following exposure of cancer cells, with wild-type but not with mutant or degraded p53 proteins, to a cytotoxic dose of adriamycin. Doxorubicin 258-268 TNF superfamily member 10 Homo sapiens 66-71 9973225-13 1999 This was evidenced by the fact that chemotherapy agents that synergized with TRAIL (e.g., doxorubicin) themselves caused cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP), and their toxicity was blocked by the caspase inhibitor Z-Val-Ala-Asp(OMe)-CH2 (ZVAD-fmk). Doxorubicin 90-101 TNF superfamily member 10 Homo sapiens 77-82 9973225-9 1999 Incubation of cell lines with doxorubicin or 5-fluorouracil significantly augmented TRAIL-induced apoptosis in most breast cell lines. Doxorubicin 30-41 TNF superfamily member 10 Homo sapiens 84-89 9973225-12 1999 Augmentation of TRAIL-induced apoptosis by doxorubicin or 5-fluorouracil was mediated through caspase activation. Doxorubicin 43-54 TNF superfamily member 10 Homo sapiens 16-21 9935184-1 1999 We report here that stress stimuli such as gamma-irradiation or the anticancer drug doxorubicin activate expression of the death-inducing ligands (DILs) CD95-L, TNF-alpha and TRAIL. Doxorubicin 84-95 TNF superfamily member 10 Homo sapiens 175-180 34360606-12 2021 AP-1 also significantly enhanced the apoptotic effect of DOX after 24 h of treatment with significant upregulation of catalase, HTRA2/Omi, FADD together with DR5 and DR4 TRAIL-mediated apoptosis (p < 0.05), contributing to the antiproliferative activity of AP-1. Doxorubicin 57-60 TNF superfamily member 10 Homo sapiens 170-175